Immune Design (IMDZ) Receives Analyst Rating

Immune Design (IMDZ) : 4 brokerage houses believe that Immune Design (IMDZ) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 4 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Immune Design (IMDZ) : The consensus price target for Immune Design (IMDZ) is $28.5 for the short term with a standard deviation of $16.26. The most optimist securities analyst among the 2 who monitor the stock believes that the stock can reach $40, however, the pessimist price target for the company is $17.


Also, Jefferies maintains its view on Immune Design (NASDAQ:IMDZ) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Jefferies lowers the price target from $20 per share to $17 per share on Immune Design . The rating by the firm was issued on August 10, 2016.

Immune Design (NASDAQ:IMDZ): The stock opened in the green at $6.26 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $6.33 and a low of $6.02 for the day. The stock did not find buyers even at the lows and closed at $6.25 recording a loss of -7.95%. 912,328 shares exchanged hands during the trading day. The stock had closed at $6.79 in the previous days trading.

Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the bodys immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action. The Companys primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and, it believes, address the shortcomings of existing therapies. The Companys immuno-oncology product candidates are being developed in two separate approaches. The Specific Antigen approach uses selected antigens that are also present in the patients tumor. The Endogenous Antigen approach relies on endogenous tumor antigens released during tumor lysis by treatments, such as chemotherapy or local radiation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.